Navigation Links
Company's Partner Completes Trial Production of a New Antiviral Medicine
Date:10/15/2007

HANGZHOU, China, Oct. 15 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that its partner, Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") has successfully completed its trial production of a new antiviral product. This all-natural medicine has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV up to 90% only in 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33. The sample product is available for distributors now and the commercial product will be available next month.

HPV infection is common across all races and socio-economic groups and is prevalent throughout the world in sexually active persons. HPVs are the most common sexually transmitted viral agents in the United States, infecting up to 20% of people aged 15 to 49. In the last 30 years, the incidence of HPV infection has increased dramatically. Despite the prevalence of HPV, no available drug therapy effectively eliminates HPV infection and replication or prevents HPV-associated malignant progression.

According to the agreement reached with Soonfast in June this year, China Biopharma has the right to distribute this new all-natural antiviral medicine in overseas market. The successful trial production has now quickened some approval process for China Biopharma to launch commercial sales on overseas market including Europe and the United States. The company and Soonfast also plan to jointly conduct studies on its extracts in both China and USA so as to obtain approval necessary for selling this medicine as an over-the-counter drug. The company believes this new medicine would bring in significant revenue and profit in the near future once it is successfully introduced into the market.

About China Biopharma, Inc.

China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese bio-pharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.

Safe Harbor Statement

Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.

CONTACT:

China Biopharma, Inc.

Tel: +1 (609) 651-8588

Attn. George Ji

ir@chinabiopharma.net

http://www.chinabiopharma.net


'/>"/>
SOURCE China Biopharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Berbees success is based on companys history and culture
2. APIs New Name Reflects Companys Current Direction
3. Detecting Your Companys Early Trouble Signs
4. Jellyfish partners for sales tracking technology
5. GE Healthcare partners with UNC on breast cancer imaging research
6. Manufacturing partnership will move into biotech and biomedical spaces
7. Fergus joins Baird Venture Partners, Caden Bio
8. Avolte Venture Partners reaches capital goal
9. NimbleGen partners with UK biotech firm
10. Big pharma seeks Wisconsin biotech partnerships
11. Thompson in partnership to build ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):